BioCentury | Jun 28, 2012
Targets & Mechanisms

Fragmentary progress in endometriosis

...and adjunct professor of medicine at Yale University . Thomas Collet, president and CEO of Meditrina Pharmaceuticals Inc....
...be advantageous" over current estrogen-suppressing therapies, said James Symons, VP of clinical development at Meditrina. Meditrina's...
...Lausanne, Switzerland Galenica Ltd. (SIX:GALN), Bern, Switzerland Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Meditrina Pharmaceuticals Inc....
BioCentury | Jun 3, 2010
Distillery Therapeutics

Indication: Neurology

...mice. AstraZeneca plc, Novartis AG and Pfizer Inc. market aromatase inhibitors to treat breast cancer. Meditrina Pharmaceuticals Inc.'s...
BioCentury | Mar 26, 2009
Distillery Therapeutics

Indication: Cancer

...cancer include AstraZeneca plc's Arimidex anastrozole, Novartis AG's Femara letrozole and Pfizer Inc.'s Aromasin exemestane. Meditrina Pharmaceuticals Inc....
BioCentury | Jul 21, 2008
Clinical News

MPI-676: Phase IIa start

...Next quarter, Meditrina will begin a double-blind, placebo-controlled, U.S. Phase IIa trial of MDI-676 in combination...
...U.S. Phase IIa trial of MDI-676 in combination with fixed-dose estrogen and progestin oral contraceptives. Meditrina Pharmaceuticals Inc....
BioCentury | Feb 11, 2008
Company News

Meditrina, AstraZeneca deal

...AstraZeneca granted Meditrina exclusive, worldwide rights to IP covering aromatase inhibitors in combination with estrogen and...
...inhibitors in combination with estrogen and progestin to treat endometriosis. Financial terms were not disclosed. Meditrina's...
...trial for endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding. Meditrina Pharmaceuticals Inc....
BioCentury | Apr 16, 2007
Product Development

Thinning the uterine wall

...which is to inhibit the aromatase enzyme that converts certain androgens to estrogen - Meditrina Pharmaceuticals Inc....
...to prevent regrowth and recurrent bleeding. Because aromatase inhibitors decrease the amount of circulating estrogen, Meditrina...
...on June 3, 2011. Femathina ( MPI-674 ) is an undisclosed marketed aromatase inhibitor that Meditrina...
BioCentury | Apr 9, 2007
Clinical News

Femathina: Phase II started

...began the placebo-controlled, U.S. Phase II M001 trial of oral MPI-674 in 68 healthy females. Meditrina Pharmaceuticals Inc....
Items per page:
1 - 7 of 7
BioCentury | Jun 28, 2012
Targets & Mechanisms

Fragmentary progress in endometriosis

...and adjunct professor of medicine at Yale University . Thomas Collet, president and CEO of Meditrina Pharmaceuticals Inc....
...be advantageous" over current estrogen-suppressing therapies, said James Symons, VP of clinical development at Meditrina. Meditrina's...
...Lausanne, Switzerland Galenica Ltd. (SIX:GALN), Bern, Switzerland Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Meditrina Pharmaceuticals Inc....
BioCentury | Jun 3, 2010
Distillery Therapeutics

Indication: Neurology

...mice. AstraZeneca plc, Novartis AG and Pfizer Inc. market aromatase inhibitors to treat breast cancer. Meditrina Pharmaceuticals Inc.'s...
BioCentury | Mar 26, 2009
Distillery Therapeutics

Indication: Cancer

...cancer include AstraZeneca plc's Arimidex anastrozole, Novartis AG's Femara letrozole and Pfizer Inc.'s Aromasin exemestane. Meditrina Pharmaceuticals Inc....
BioCentury | Jul 21, 2008
Clinical News

MPI-676: Phase IIa start

...Next quarter, Meditrina will begin a double-blind, placebo-controlled, U.S. Phase IIa trial of MDI-676 in combination...
...U.S. Phase IIa trial of MDI-676 in combination with fixed-dose estrogen and progestin oral contraceptives. Meditrina Pharmaceuticals Inc....
BioCentury | Feb 11, 2008
Company News

Meditrina, AstraZeneca deal

...AstraZeneca granted Meditrina exclusive, worldwide rights to IP covering aromatase inhibitors in combination with estrogen and...
...inhibitors in combination with estrogen and progestin to treat endometriosis. Financial terms were not disclosed. Meditrina's...
...trial for endometrial thinning prior to endometrial ablations in premenopausal women with abnormal uterine bleeding. Meditrina Pharmaceuticals Inc....
BioCentury | Apr 16, 2007
Product Development

Thinning the uterine wall

...which is to inhibit the aromatase enzyme that converts certain androgens to estrogen - Meditrina Pharmaceuticals Inc....
...to prevent regrowth and recurrent bleeding. Because aromatase inhibitors decrease the amount of circulating estrogen, Meditrina...
...on June 3, 2011. Femathina ( MPI-674 ) is an undisclosed marketed aromatase inhibitor that Meditrina...
BioCentury | Apr 9, 2007
Clinical News

Femathina: Phase II started

...began the placebo-controlled, U.S. Phase II M001 trial of oral MPI-674 in 68 healthy females. Meditrina Pharmaceuticals Inc....
Items per page:
1 - 7 of 7